

Sage Therapeutics, Inc.  
Form SC 13G/A  
February 13, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 13G**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**  
**(Amendment No. 2)\***

**Sage Therapeutics, Inc.**  
**(Name of Issuer)**

**COMMON STOCK, \$0.0001 PAR VALUE PER SHARE**  
**(Title of Class of Securities)**

**78667J108**  
**(CUSIP Number)**

**December 31, 2016**  
**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 78667J108

SCHEDULE 13G

Page 2 of 12 Pages

1. NAMES OF REPORTING PERSONS

**Third Rock Ventures II, L.P.**

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES 0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 2,892,916

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 0

8. SHARED DISPOSITIVE POWER

WITH

2,892,916

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,892,916

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

7.8% (1)

12. TYPE OF REPORTING PERSON

PN

- (1) The percent of class was calculated based on 37,167,174 shares of common stock issued and outstanding as of November 1, 2016, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2016.

CUSIP No. 78667J108

SCHEDULE 13G

Page 3 of 12 Pages

1. NAMES OF REPORTING PERSONS

**Third Rock Ventures GP II, L.P.**

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES 0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 2,892,916

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 0

8. SHARED DISPOSITIVE POWER

WITH

2,892,916

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,892,916

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 7.8% (1)  
TYPE OF REPORTING PERSON

PN

CUSIP No. 78667J108

SCHEDULE 13G

Page 4 of 12 Pages

1. NAMES OF REPORTING PERSONS

**TRV GP II, LLC**

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES 0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 2,892,916

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 0

8. SHARED DISPOSITIVE POWER

WITH

2,892,916

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,892,916

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 7.8% (1)  
TYPE OF REPORTING PERSON

OO

CUSIP No. 78667J108

SCHEDULE 13G

Page 5 of 12 Pages

1. NAMES OF REPORTING PERSONS

**Mark Levin**

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

NUMBER OF

SHARES 138,917  
6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 2,892,916  
EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 138,917  
8. SHARED DISPOSITIVE POWER

WITH

2,892,916  
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,031,833  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 8.2% (1)  
TYPE OF REPORTING PERSON

IN

1. NAMES OF REPORTING PERSONS

**Kevin P. Starr**

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

NUMBER OF

SHARES 152,840 (2)  
6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 2,892,916  
EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 152,840 (2)  
8. SHARED DISPOSITIVE POWER

WITH

2,892,916  
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,045,756 (2)  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 8.2% (1)  
TYPE OF REPORTING PERSON

IN

(2) This number includes options to purchase 13,922 shares of common stock exercisable within 60 days of December 31, 2016.

CUSIP No. 78667J108

SCHEDULE 13G

Page 7 of 12 Pages

1. NAMES OF REPORTING PERSONS

**Robert I. Tepper**

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

NUMBER OF

SHARES 138,917  
6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 2,892,916  
EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 138,917  
8. SHARED DISPOSITIVE POWER

WITH

2,892,916  
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,031,833  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 8.2% (1)  
TYPE OF REPORTING PERSON

IN

CUSIP No. 78667J108

SCHEDULE 13G

Page 8 of 12 Pages

**Item 1. Issuer**

- (a) Name of Issuer:  
Sage Therapeutics, Inc. (the **Issuer** )
- (b) Address of Issuer's Principal Executive Offices:  
215 First Street  
  
Cambridge, MA 02142

**Item 2. Filing Person**

- (a) (c) Name of Persons Filing; Address; Citizenship:
- (i) Third Rock Ventures II, L.P. ( **TRV II** );
  - (ii) Third Rock Ventures GP II, L.P. ( **TRV GP II** ), which is the sole general partner of TRV II;
  - (iii) TRV GP II, LLC ( **TRV GP II LLC** ), which is the sole general partner of TRV GP II;
  - (iv) Mark Levin ( **Levin** ), a managing member of TRV GP II LLC;
  - (v) Kevin P. Starr ( **Starr** ), a managing member of TRV GP II LLC; and
  - (vi) Robert I. Tepper ( **Tepper**, and collectively with TRV II, TRV GP II, TRV GP II LLC, Levin and Starr, the **Reporting Persons** ), a managing member of TRV GP II LLC.

The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 29 Newbury Street, 3rd Floor, Boston, MA 02116.

Each of TRV II and TRV GP II is a Delaware limited partnership. TRV GP II LLC is a Delaware limited liability company. Levin, Tepper and Starr are United States citizens.

- (d) Title of Class of Securities:  
Common stock, \$0.0001 par value per share, (the **Common Stock** ).
- (e) CUSIP Number:

78667J108

**Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:**

- (a) Broker or dealer registered under Section 15 of the Act;
- (b) Bank as defined in Section 3(a)(6) of the Act;
- (c) Insurance company as defined in Section 3(a)(19) of the Act;

Edgar Filing: Sage Therapeutics, Inc. - Form SC 13G/A

- (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j) A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

#### Item 4. Ownership.

(a) and (b) Amount beneficially owned:

- (i) TRV II directly owns 2,892,916 shares of Common Stock (the **Shares** ), which represents approximately 7.8% of the outstanding shares of Common Stock.
- (ii) TRV GP II is the general partner of TRV II and may be deemed to beneficially own the Shares.
- (iii) TRV GP II LLC is the general partner of TRV GP II and may be deemed to beneficially own the Shares.
- (iv) As a managing member of TRV GP II LLC, Levin may be deemed to beneficially own the Shares. Additionally, as of December 31, 2016, Levin directly owns 138,917 shares of Common Stock, which represents 0.4% of the outstanding shares of Common Stock. As a result, Levin may be deemed to beneficially own an aggregate of 3,031,833 shares of Common Stock, which represents approximately 8.2% of the outstanding shares of Common Stock.
- (v) As a managing member of TRV GP II LLC, Tepper may be deemed to beneficially own the Shares. Additionally, as of December 31, 2016, Tepper directly owns 138,917 shares of Common Stock, which represents 0.4% of the outstanding shares of Common Stock. As a result, Tepper may be deemed to beneficially own an aggregate of 3,031,833 shares of Common Stock, which represents approximately 8.2% of the outstanding shares of Common Stock.
- (vi) As a managing member of TRV GP II LLC, Starr may be deemed to beneficially own the Shares. Additionally, as of December 31, 2016, Starr directly owns 138,918 shares of Common Stock and 13,922 shares of Common Stock issuable upon the exercise of outstanding options within 60 days of December 31, 2016, which collectively represent 0.4% of the outstanding shares of Common Stock. As a result, Starr may be deemed to beneficially own an aggregate of 3,045,756 shares of Common Stock, which represents approximately 8.2% of the outstanding shares of Common Stock.

(c) Number of shares as to which such person has:

Reporting Person	Number of Shares of Common Stock			
	(i)	(ii)	(iii)	(iv)
TRV II		2,892,916		2,892,916
TRV GP II		2,892,916		2,892,916
TRV GP II LLC		2,892,916		2,892,916
Levin	138,917	2,892,916	138,917	2,892,916
Starr	152,840	2,892,916	152,840	2,892,916
Tepper	138,917	2,892,916	138,917	2,892,916

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote

- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

The percent of class was calculated based on 37,167,174 shares of common stock issued and outstanding as of November 1, 2016, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2016.

**Item 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certification.**

Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2017

**THIRD ROCK VENTURES II, L.P.**

By: THIRD ROCK VENTURES GP II, L.P.,  
General Partner

By: TRV GP II, LLC,  
General Partner

By: /s/ Kevin Gillis  
Kevin Gillis  
Chief Financial Officer

**THIRD ROCK VENTURES GP II, L.P.**

By: TRV GP II, LLC,  
General Partner

By: /s/ Kevin Gillis  
Kevin Gillis  
Chief Financial Officer

**TRV GP II, LLC**

By: /s/ Kevin Gillis  
Kevin Gillis  
Chief Financial Officer

**MARK LEVIN**

/s/ Kevin Gillis, As attorney-in-fact  
Mark Levin

**KEVIN P. STARR**

/s/ Kevin Gillis, As attorney-in-fact  
Kevin P. Starr

CUSIP No. 78667J108

SCHEDULE 13G

Page 12 of 12 Pages

**ROBERT I. TEPPER**

/s/ Kevin Gillis, As attorney-in-fact  
Robert I. Tepper